Oncimmune Holdings PLC Oncimmune signs US distribution agreement
December 20 2018 - 8:13AM
RNS Non-Regulatory
TIDMONC
Oncimmune Holdings PLC
20 December 2018
Oncimmune Signs Agreement with America's Choice Provider Network
to Expand Access to its Blood Tests for the Early Detection of Lung
and Liver Cancers
De Soto, Kansas, December 20, 2018 - Oncimmune Holdings plc
(AIM: ONC.L), a leader in the development, manufacture and
commercialization of personalized immunodiagnostics for the
screening, detection and care of cancer, today announced that it
has entered into an agreement with America's Choice Provider
Network (ACPN) to expand access to Oncimmune's simple and
affordable blood tests, EarlyCDT(R) -Lung and EarlyCDT(R) -Liver.
ACPN is an independent, multi-specialty provider network accessed
by over 1,700 payers. More than 28 million Americans and 750,000
international lives have access to ACPN's network.
EarlyCDT-Lung is used by clinicians to assess lung cancer risk
in high-risk patients who have an indeterminate pulmonary nodule
(IPN), and is highly specific in detecting all types of lung cancer
at all stages of disease. These attributes make the test
complementary to the high sensitivity but poor specificity of CT
scanning. EarlyCDT-Liver aids in the detection and confirmation of
hepatocellular carcinoma (HCC, liver cancer), in association with
imaging, in high-risk patients with liver lesions of all sizes.
"Our collaboration with America's Choice Provider Network is one
of several payor and provider agreements we have recently finalized
to ensure as many people as possible in the U.S. are able to use
our EarlyCDT(R) tests to facilitate earlier diagnoses," said Marco
Casarin, General Manager, Oncimmune (USA) LLC. "Especially in lung
cancer-with nearly 1.6 million Americans having an incidentally
detected nodule on the lung-a positive EarlyCDT-Lung outcome
enables quicker clinician intervention and better patient
outcomes."
About Oncimmune(R)
Oncimmune is changing how clinicians, researchers and patients
view, diagnose and treat cancer. Our technology detects evidence of
the body's natural response to cancer, enabling detection four
years or more before standard clinical diagnosis. Our tests
facilitate clinical decision-making and are complementary to
diagnostic technologies, making them valuable additions to
established and new care pathways. We partner with leading
developers and distributors to make our technology available
globally.
Oncimmune launched its platform technology in 2009, followed by
its first commercial tests, EarlyCDT(R) -Lung and EarlyCDT(R)
-Liver. To date, over 155,000 tests have been performed for
patients worldwide. EarlyCDT-Lung is being used in the National
Health Service (NHS) ECLS study of 12,210 high-risk smokers in
Scotland, which is the largest-ever randomized trial for the early
detection of lung cancer using biomarkers.
Oncimmune is headquartered in Nottingham, UK, with a CLIA lab in
Kansas, U.S. and offices in London, UK and Shanghai, China.
Oncimmune joined the Alternative Investment Market (AIM) of the
London Stock Exchange in May 2016 under the ticker ONC.L.
For more information, visit http://oncimmune.com/. Follow us on
Twitter and LinkedIn.
Media Contacts:
RAliance Communications
Reba Auslander
reba@raliancecommunications.com
917-836-9308
Consilium Strategic Communications
Chris Gardner, Matthew Neal, Lindsey Neville
Oncimmune@consilium-comms.com
+44 (0)20 3709 5708
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
NRAURASRWAAUUAA
(END) Dow Jones Newswires
December 20, 2018 09:13 ET (14:13 GMT)
Oncimmune (LSE:ONC)
Historical Stock Chart
From Apr 2024 to May 2024
Oncimmune (LSE:ONC)
Historical Stock Chart
From May 2023 to May 2024